DK3851537T3 - Behandling af hyperbilirubinæmi - Google Patents

Behandling af hyperbilirubinæmi Download PDF

Info

Publication number
DK3851537T3
DK3851537T3 DK21151019.3T DK21151019T DK3851537T3 DK 3851537 T3 DK3851537 T3 DK 3851537T3 DK 21151019 T DK21151019 T DK 21151019T DK 3851537 T3 DK3851537 T3 DK 3851537T3
Authority
DK
Denmark
Prior art keywords
hyperbilirubinamia
treatment
Prior art date
Application number
DK21151019.3T
Other languages
English (en)
Inventor
Federico Mingozzi
Giuseppe Ronzitti
Fanny Collaud
Andrés Muro
Giulia Bortolussi
Original Assignee
Genethon
Int Centre For Genetic Engineering And Biotechnology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genethon, Int Centre For Genetic Engineering And Biotechnology filed Critical Genethon
Application granted granted Critical
Publication of DK3851537T3 publication Critical patent/DK3851537T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1051—Hexosyltransferases (2.4.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)
    • C12Y204/01—Hexosyltransferases (2.4.1)
    • C12Y204/01017—Glucuronosyltransferase (2.4.1.17)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
DK21151019.3T 2014-04-25 2015-04-27 Behandling af hyperbilirubinæmi DK3851537T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14305622 2014-04-25
EP14196400 2014-12-04
EP19172023.4A EP3546585A1 (en) 2014-04-25 2015-04-27 Treatment of hyperbilirubinemia

Publications (1)

Publication Number Publication Date
DK3851537T3 true DK3851537T3 (da) 2024-03-18

Family

ID=53039406

Family Applications (2)

Application Number Title Priority Date Filing Date
DK15719677.5T DK3134530T3 (da) 2014-04-25 2015-04-27 Behandling af hyperbilirubinæmi
DK21151019.3T DK3851537T3 (da) 2014-04-25 2015-04-27 Behandling af hyperbilirubinæmi

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK15719677.5T DK3134530T3 (da) 2014-04-25 2015-04-27 Behandling af hyperbilirubinæmi

Country Status (10)

Country Link
US (3) US10471132B2 (da)
EP (3) EP3546585A1 (da)
JP (3) JP6730193B2 (da)
CN (2) CN114395559A (da)
AU (1) AU2015250770B2 (da)
CA (2) CA3205555A1 (da)
DK (2) DK3134530T3 (da)
ES (1) ES2744565T3 (da)
FI (1) FI3851537T3 (da)
WO (1) WO2015162302A2 (da)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100183558A1 (en) 2008-10-17 2010-07-22 Zhennan Lai Safe lentiviral vectors for targeted delivery of multiple therapeutic molecules
GB201420139D0 (en) 2014-11-12 2014-12-24 Ucl Business Plc Factor IX gene therapy
US20190307857A1 (en) * 2015-12-09 2019-10-10 Modernatx, Inc. MODIFIED mRNA ENCODING A URIDINE DIPHOPSPHATE GLUCURONOSYL TRANSFERASE AND USES THEREOF
AU2016370590B2 (en) * 2015-12-14 2023-11-02 The Trustees Of The University Of Pennsylvania Composition for treatment of Crigler-Najjar syndrome
US11072803B2 (en) 2015-12-22 2021-07-27 Inserm (Institut National De La Sante Et De La Recherche Medicale) Hybrid dual recombinant AAV vector systems for gene therapy
DK3402483T3 (da) 2016-01-15 2024-01-02 American Gene Tech Int Inc Fremgangsmåder og sammensætninger til aktivering af gamma-delta-T-celler
US10137144B2 (en) 2016-01-15 2018-11-27 American Gene Technologies International Inc. Methods and compositions for the activation of gamma-delta T-cells
US10888613B2 (en) 2016-02-08 2021-01-12 American Gene Technologies International Inc. Method of producing cells resistant to HIV infection
WO2017156311A2 (en) 2016-03-09 2017-09-14 American Gene Technologies International Inc. Combination vectors and methods for treating cancer
CN105721252B (zh) * 2016-03-24 2020-09-25 腾讯科技（深圳）有限公司 数据包乱序度的测量方法和系统
GB201608046D0 (en) * 2016-05-09 2016-06-22 Cambridge Entpr Ltd And Syndey Children S Hospitals Network Randwick And Westmead Incorporating The Treatment of complement-mediated disorders
JP6971492B2 (ja) 2016-07-08 2021-11-24 アメリカン ジーン テクノロジーズ インターナショナル インコーポレイテッド Ｈｉｖ予備免疫化および免疫療法
JP7176756B2 (ja) 2016-07-21 2022-11-22 アメリカン ジーン テクノロジーズ インターナショナル インコーポレイテッド パーキンソン病を処置するためのウイルスベクター
EP3293203A1 (en) 2016-09-12 2018-03-14 Genethon Acid-alpha glucosidase variants and uses thereof
EP3293259A1 (en) 2016-09-12 2018-03-14 Genethon Acid-alpha glucosidase variants and uses thereof
EP3293260A1 (en) 2016-09-12 2018-03-14 Genethon Acid-alpha glucosidase variants and uses thereof
SG11201901494UA (en) 2016-09-12 2019-03-28 Genethon Acid-alpha glucosidase variants and uses thereof
US11541131B2 (en) 2017-03-10 2023-01-03 Genethon Treatment of glycogen storage disease III
US11820999B2 (en) 2017-04-03 2023-11-21 American Gene Technologies International Inc. Compositions and methods for treating phenylketonuria
EP3648783A1 (en) * 2017-07-07 2020-05-13 Genethon Novel polynucleotides encoding a human fkrp protein
WO2019070674A2 (en) * 2017-10-02 2019-04-11 American Gene Technologies International Inc. VECTORS COMPRISING PROMOTER AND ACTIVATOR COMBINATIONS FOR THE TREATMENT OF PHENYLCETONURIA
CN111902539A (zh) 2018-02-07 2020-11-06 吉尼松公司 杂合调控元件
JP7142815B2 (ja) * 2018-06-21 2022-09-28 株式会社遺伝子治療研究所 ヒト肝臓への遺伝子導入のためのアデノ随伴ウイルスビリオン
CN109082402B (zh) * 2018-08-06 2021-08-17 复旦大学 一种aav-dj型腺相关病毒体外高效感染类器官的用途
MA53268B1 (fr) 2018-08-08 2023-06-28 Univ Sorbonne Mini-gde pour le traitement de maladies de stockage de glycogène de type iii
US10842885B2 (en) 2018-08-20 2020-11-24 Ucl Business Ltd Factor IX encoding nucleotides
EP3864161A4 (en) * 2018-10-09 2022-11-23 The University of North Carolina at Chapel Hill REGULATED GENE EDIT SYSTEM
JP2022516010A (ja) * 2018-12-21 2022-02-24 ジェネトン 遺伝子療法ベクターのための発現カセット
CA3151442A1 (en) 2019-10-22 2021-04-29 Pasqualina COLELLA Sortilin receptor ligand based chimeric polypeptides and uses thereof
WO2021078834A1 (en) 2019-10-22 2021-04-29 Genethon Chimeric acid-alpha glucosidase polypeptides and uses thereof
EP3913060A1 (en) 2020-05-22 2021-11-24 Genethon Vectors encoding a glucose-6-phosphatase (g6pase-a) for gene therapy
US20230313152A1 (en) 2020-08-24 2023-10-05 Genethon C-terminal truncated gde for the treatment of glycogen storage disease iii
IL301955A (en) 2020-10-07 2023-06-01 Asklepios Biopharmaceutical Inc Therapeutic delivery of an adeno-related protein-related protein (FKRP) virus for the treatment of dystroglycanopathy disorders, including limb girdle 21
WO2022177597A1 (en) * 2021-02-16 2022-08-25 The Board Of Trustees Of The Leland Stanford Junior University Systems and methods to enhance rna stability and translation and uses thereof
WO2023237731A1 (en) 2022-06-09 2023-12-14 Genethon N-terminal truncated gde for the treatment of glycogen storage disease iii

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2063799A1 (en) * 1989-07-24 1991-01-25 Frank S. Genbauffe Prevention of internal initiation
WO1997021824A2 (en) * 1995-12-15 1997-06-19 Systemix, Inc. Method for obtaining retroviral vector supernatant having high transduction efficiency
US5910434A (en) * 1995-12-15 1999-06-08 Systemix, Inc. Method for obtaining retroviral packaging cell lines producing high transducing efficiency retroviral supernatant
AU2002211710A1 (en) * 2000-10-13 2002-04-22 Chiron Corporation Cytomegalovirus intron a fragments
US7704721B2 (en) 2004-06-01 2010-04-27 Genzyme Corporation Compositions and methods to prevent AAV vector aggregation
WO2006102643A2 (en) * 2005-03-24 2006-09-28 Caritas St. Elizabeth Medical Center Boston, Inc. Stably transformed bone marrow-derived cells and uses thereof
CN101213203A (zh) 2005-04-29 2008-07-02 教堂山北卡罗莱纳州大学 在转录后水平调节核酸表达的方法和组合物
WO2007120533A2 (en) * 2006-03-30 2007-10-25 The Board Of Trustees Of The Leland Stanford Junior University Minigene expression cassette
KR101229418B1 (ko) 2007-06-15 2013-02-05 재단법인 목암생명공학연구소 활성형 재조합 혈액응고 9인자의 대량생산 방법
EP2014301A1 (en) * 2007-07-13 2009-01-14 TopoTarget Germany AG Optimized DNA and protein sequence of an antibody to improve quality and yield of bacterially expressed antibody fusion proteins
CN101348786B (zh) * 2007-07-20 2011-05-11 谭孟群 一种人β珠蛋白基因及其重组腺相关病毒载体
EP2352823B1 (en) * 2008-09-29 2014-08-06 UniQure IP B.V. Porphobilinogen deaminase gene therapy
CN101671740B (zh) * 2009-10-19 2012-05-23 广州益善生物技术有限公司 Ugt1a1基因多态性检测的方法及液相芯片
CA2779689A1 (en) * 2009-11-06 2011-05-12 Enzymatics, Inc. Composition and method for synthesizing a deoxyribonucleotide chain using a double stranded nucleic acid complex with a thermostable polymerase
WO2011106759A1 (en) * 2010-02-26 2011-09-01 The Children's Hospital Of Philadelphia Protein c zymogen and methods of use thereof to prevent cancer metastases
CN104321069A (zh) * 2011-10-27 2015-01-28 威尔斯达眼科制剂公司 编码视杆细胞来源的视锥细胞活力因子的载体
CN102643906A (zh) * 2012-04-01 2012-08-22 周宏灏 焦磷酸测序法检测伊立替康个体化用药基因多态性的试剂盒及方法
AU2013243949A1 (en) * 2012-04-02 2014-10-30 Moderna Therapeutics, Inc. Modified polynucleotides for the production of biologics and proteins associated with human disease
EP2876161B1 (en) * 2012-07-23 2018-12-05 The Institute of Biological Resources Vaccine
CN103146804B (zh) * 2013-02-04 2015-04-22 中国科学院大连化学物理研究所 葡萄糖醛酸转移酶ugt1a1的特异性探针底物及应用
PT3024498T (pt) 2013-07-22 2020-03-06 Childrens Hospital Philadelphia Variante aav e composições, métodos e usos para transferência genética em células, órgãos e tecidos
CN104789532B (zh) * 2015-03-30 2019-06-11 汉恒生物科技（上海）有限公司 一种表达腺病毒的细胞株及高效制备腺病毒的方法

Also Published As

Publication number Publication date
JP2017513501A (ja) 2017-06-01
WO2015162302A2 (en) 2015-10-29
US10471132B2 (en) 2019-11-12
US20170028036A1 (en) 2017-02-02
JP7349931B2 (ja) 2023-09-25
CN106459932A (zh) 2017-02-22
EP3134530B1 (en) 2019-06-12
JP2020103300A (ja) 2020-07-09
ES2744565T3 (es) 2020-02-25
AU2015250770A1 (en) 2016-09-29
JP6730193B2 (ja) 2020-07-29
CN114395559A (zh) 2022-04-26
EP3134530A2 (en) 2017-03-01
US20190374619A1 (en) 2019-12-12
US20230414724A1 (en) 2023-12-28
JP2022088645A (ja) 2022-06-14
CA3205555A1 (en) 2015-10-29
EP3851537B1 (en) 2023-12-27
FI3851537T3 (fi) 2024-03-21
WO2015162302A3 (en) 2015-12-30
DK3134530T3 (da) 2019-09-09
CN106459932B (zh) 2022-01-11
EP3546585A1 (en) 2019-10-02
AU2015250770B2 (en) 2020-10-01
CA2942451A1 (en) 2015-10-29
EP3851537A1 (en) 2021-07-21

Similar Documents

Publication Publication Date Title
DK3851537T3 (da) Behandling af hyperbilirubinæmi
DK3137169T3 (da) Hæmmere af lysin-specifik demethylase-1
DK3102576T3 (da) Dihydropyrrolopyridininhibitorer af ror-gamma
DK3125875T3 (da) Inhalerbar rapamycinformulering til behandling af aldersrelaterede tilstande
DK3180331T3 (da) Polymorfer af selinexor
DK3160956T3 (da) Inhibitorer af lysin-specifik demethylase-1
DK3164380T3 (da) Hæmmere af lysinspecifik demethylase-1
DK3461891T3 (da) Nedstrømsbehandling af en alkalisk phosphatase
DK2968208T3 (da) Behandling af kataplexi
DK3240612T3 (da) Fremgangsmåder til behandling af nethindesygdomme
DK3231444T3 (da) Ny behandling
DK3307267T3 (da) Behandling af multipel sklerose
DK3283210T3 (da) Fremgangsmåde
DK3132009T3 (da) Fremgangsmåde
DK3368044T3 (da) Behandling af hepatisk steatose-relateret oligo-ovulation
DK3201323T3 (da) Modificering af bakteriofag
DK3204352T3 (da) Hæmmere af lysin-gingipain
DK3237621T3 (da) Varianter af human alpha-galactosidase
DK3297619T3 (da) Terapeutiske anvendelser af L-4-chlorkynurenin
DK3143123T3 (da) Mikrorna-induktion af kardiologisk regenerering
DK3122349T3 (da) Sammensætninger til behandling af autodigestion
DK2897382T3 (da) Forbedring af binaural kilde
DK3151814T3 (da) Behandling af en hudlæsion
DK3418273T3 (da) Derivater af flavagliner
DK3209295T4 (da) Fremgangsmåder til behandling af øjenlidelser